文献速递糖尿病

恩格列净导致2型糖尿病患者葡萄糖生成与酮体形成增加的机制不同

Distinct Mechanisms Responsible for the Increase in Glucose Production and Ketone Formation Caused by Empagliflozin in T2DM Patients.
PubMed 文献 · Diabetes Care · 2023-01-01

12例2型糖尿病患者随机顺序参与两项研究,研究1输注6,6,D2-葡萄糖测内源性葡萄糖生成(EGP),3小时后8例服恩格列净25 mg、4例服安慰剂,并用3H-去甲肾上腺素测更新率;研究2在胰腺钳夹条件下重复。结果显示空腹服恩格列净使EGP升高31%,伴血糖降34 mg/dL、胰岛素降52%、胰高血糖素升19%、游离脂肪酸升29%、β-羟丁酸升48%;胰腺钳夹下胰岛素和胰高血糖素不变,游离脂肪酸和酮体升高被完全阻断,EGP升高持续;全身去甲肾上腺素更新率在恩格列净组较安慰剂组高67%。结论认为胰岛素下降和胰高血糖素升高导致游离脂肪酸和酮体增加,EGP增加独立于此,可能由去甲肾上腺素更新率增加解释。

要点

  • 空腹服恩格列净25 mg使EGP升高31%,伴胰岛素降52%、胰高血糖素升19%。
  • 胰腺钳夹下胰岛素和胰高血糖素不变,游离脂肪酸和酮体升高被完全阻断,EGP升高持续。
  • 全身去甲肾上腺素更新率恩格列净组较安慰剂组高67%,EGP升高可能由其解释。

核心结论

  • 恩格列净引起的血浆胰岛素下降和胰高血糖素升高导致血浆游离脂肪酸浓度和酮体生成增加。
  • 恩格列净引起的EGP增加独立于血浆胰岛素或胰高血糖素浓度变化,可能由去甲肾上腺素更新率增加解释。

研究设计与样本

  • 12例2型糖尿病患者随机顺序参与两项研究。
  • 研究1以6,6,D2-葡萄糖输注8小时测EGP,开始输注3小时后8例服恩格列净25 mg、4例服安慰剂,并用3H-去甲肾上腺素输注测去甲肾上腺素更新率。
  • 研究2与研究1相似,但在胰腺钳夹条件下进行。

主要发现

  • 空腹服恩格列净后EGP升高31%,伴血浆葡萄糖降34 mg/dL、胰岛素降52%、胰高血糖素升19%、游离脂肪酸升29%、β-羟丁酸升48%。
  • 胰腺钳夹下服恩格列净后血浆胰岛素和胰高血糖素浓度不变,血浆游离脂肪酸和酮体浓度升高被完全阻断,而EGP升高持续。
  • 空腹和胰腺钳夹条件下,恩格列净组全身去甲肾上腺素更新率较安慰剂组高67%。
  • 两项研究中均未观察到血浆去甲肾上腺素浓度差异。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the mechanisms responsible for the increase in glucose and ketone production caused by empagliflozin in patients with type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: Twelve subjects with T2DM participated in two studies performed in random order. In study 1, endogenous glucose production (EGP) was measured with 8-h infusion of 6,6,D2-glucose. Three hours after the start of 6,6,D2-glucose infusion, subjects ingested 25 mg empagliflozin (n = 8) or placebo (n = 4), and norepinephrine (NE) turnover was measured before and after empagliflozin ingestion with 3H-NE infusion. Study 2 was similar to study 1 but performed under pancreatic clamp conditions. RESULTS: When empagliflozin was ingested under fasting conditions, EGP increased by 31% in association with a decrease in plasma glucose (-34 mg/dL) and insulin (-52%) concentrations and increases in plasma glucagon (+19%), free fatty acid (FFA) (+29%), and β-hydroxybutyrate (+48%) concentrations. When empagliflozin was ingested under pancreatic clamp conditions, plasma insulin and glucagon concentrations remained unchanged, and the increase in plasma FFA and ketone concentrations was completely blocked, while the increase in EGP persisted. Total-body NE turnover rate was greater in subjects receiving empagliflozin (+67%) compared with placebo under both fasting and pancreatic clamp conditions. No difference in plasma NE concentration was observed in either study. CONCLUSIONS: The decrease in plasma insulin and increase in plasma glucagon concentration caused by empagliflozin is responsible for the increase in plasma FFA concentration and ketone production. The increase in EGP caused by empagliflozin is independent of the change in plasma insulin or glucagon concentrations and is likely explained by the increase in NE turnover.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Abdelgani S, Khattab A, Adams J, et al. Distinct Mechanisms Responsible for the Increase in Glucose Production and Ketone Formation Caused by Empagliflozin in T2DM Patients. Diabetes Care. 2023. PMID: 36857415. doi:10.2337/dc22-0885

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。